FMR1

Official Full Name

fragile X messenger ribonucleoprotein 1

Organism

Homo sapiens

GeneID

2332

Background

The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm. A trinucleotide repeat (CGG) in the 5' UTR is normally found at 6-53 copies, but an expansion to 55-230 repeats is the cause of fragile X syndrome. Expansion of the trinucleotide repeat may also cause one form of premature ovarian failure (POF1). Multiple alternatively spliced transcript variants that encode different protein isoforms and which are located in different cellular locations have been described for this gene. [provided by RefSeq, May 2010]

Synonyms

POF; FMRP; POF1; FRAXA;

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Cat.No.	Product Name	Price

Detailed Information

The FMR1 gene, located on human chromosome Xq27.3, encodes the Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein. FMRP contains two KH-type domains at its N-terminus and an RGG box at its C-terminus, which together mediate broad binding to a large set of specific mRNAs. A hallmark feature of FMR1 is an unstable CGG trinucleotide repeat in its 5′ untranslated region (5′UTR). In healthy individuals, the CGG repeat typically ranges from 6 to 53 copies (normal polymorphic range). When expanded to 55–200 copies ("premutation" range), carriers usually do not exhibit classic Fragile X Syndrome (FXS) but may be at risk for other related disorders. When the repeat exceeds 200 copies ("full mutation" range), it triggers aberrant promoter methylation, epigenetically silencing FMR1 transcription and leading to a severe deficiency or absence of FMRP protein, which is the molecular basis of Fragile X Syndrome, the most common inherited form of intellectual disability and a monogenic cause of autism spectrum disorder.

Figure 1. Structure of the FMR1 gene and its allelic variants. (Tabolacci E, et al., 2016)

Biological Significance

FMRP is a multifunctional, ribosome-associated RNA-binding protein central to neuronal development and synaptic plasticity. It precisely regulates multiple stages of the mRNA lifecycle, including alternative splicing, stability, nuclear–cytoplasmic transport, and, critically, local translation at synapses. Under basal conditions, FMRP generally acts as a translation repressor, binding hundreds of mRNAs encoding pre- and postsynaptic proteins and inhibiting their translation through mechanisms such as recruitment of translational repressor complexes, ribosome stalling, or promoting mRNA deadenylation. This repression is essential for maintaining synaptic stability and is a molecular basis for synaptic plasticity.

FMRP-mediated translation repression is dynamically regulated. Upon activation of metabotropic glutamate receptors (mGluRs), FMRP is rapidly phosphorylated and dissociates from target mRNAs, resulting in rapid derepression and localized dendritic protein synthesis, a process critical for long-term depression and certain forms of learning and memory. Additionally, FMRP undergoes liquid–liquid phase separation, forming cytoplasmic ribonucleoprotein granules that act as transport and storage units for mRNAs, releasing them for translation upon synaptic activation. Beyond translation control, FMRP also regulates mRNA nuclear export, specifically recognizing N6-methyladenosine-modified mRNAs and facilitating their cytoplasmic transport. Emerging evidence suggests FMRP may also modulate ion channel activity, influencing neuronal excitability and neurotransmitter release independently of RNA binding.

Clinical Relevance

FMR1-related disorders stem from its gene mutations and repeat expansions. Fragile X Syndrome (FXS) arises from full mutation CGG expansions, causing near-complete loss of FMRP. Patients exhibit moderate to severe intellectual disability, social anxiety, attention deficits, hyperactivity, and characteristic physical features such as elongated face and large ears. Males are typically more severely affected due to X-linked inheritance. Current management focuses on behavioral therapy, educational support, and symptomatic pharmacological treatment, while understanding FMRP's role in synaptic dysfunction guides potential disease-modifying therapies, such as mGluR5 antagonists, though clinical success remains limited.

Premutation carriers (55–200 CGG repeats) can develop two main conditions:

Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) – a progressive neurodegenerative disorder typically affecting older male carriers, driven by RNA toxicity rather than FMRP loss.
Fragile X-associated Primary Ovarian Insufficiency (FXPOI) – affecting some female carriers, resulting in premature ovarian failure.

Diagnostic confirmation relies on CGG repeat quantification in FMR1. Future therapeutic strategies may include gene therapy (viral delivery of functional FMR1), gene editing to reactivate silenced alleles, or small molecules that mimic FMRP function or correct downstream pathway dysregulation. In-depth understanding of FMR1 and FMRP not only elucidates a major neurodevelopmental disorder mechanism but also enhances insights into mRNA translation control at synapses as a core determinant of cognitive function.

References

Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60(2):201–214.
Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247–261.
Tabolacci E, Palumbo F, Nobile V, et al. Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome. Genes (Basel). 2016 Aug 17;7(8):49.

Quick Inquiry

Interested in learning more?

Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.

Request a quote today!

Inquiry